Newborn Screening for Mitochondrial Carnitine-Acylcarnitine Cycle Disorders in Zhejiang Province, China

Duo Zhou1, Yi Cheng1, Xiaoshan Yin2, Haixia Miao1, Zhenzhen Hu1, Jianbin Yang1, Yu Zhang3, Benqing Wu4* and Xinwen Huang1*

1Department of Genetics and Metabolism, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Regional Medical Center for Children, Hangzhou, China; 2School of Health in Social Science, The University of Edinburg, Edinburg, United Kingdom; 3Zhejiang Bosheng Biotechnology Co, Ltd, Hangzhou, China; 4Children’s Medical Center, University of Chinese Academy of Science - Shenzhen Hospital, Shenzhen, China

Background: Disorders of mitochondrial carnitine–acylcarnitine cycle is a heterogeneous group of hereditary diseases of mitochondrial β-oxidation of fatty acids tested in NBS program in Zhejiang province, China. Large-scale studies reporting disorders of mitochondrial carnitine–acylcarnitine cycle among Chinese population in NBS are limited. The aim of this study was to explain the incidence and biochemical, clinical, and genetic characteristics of disorders of mitochondrial carnitine–acylcarnitine cycle in NBS.

Methods: From January 2009 to June 2021, 4,070,375 newborns were screened by tandem mass spectrometry. Newborns with elevated C0 levels and/or C0/(C16 + C18) ratios were identified as having CPT1D, whereas those with decreased C0 levels and/or C0/(C16 + C18) ratios and/or elevated C12-C18:1 level were identified as having CPT2D or CACTD. Suspected positive patients were further subjected to genetic analysis. All confirmed patients received biochemical and nutritional treatment, as well as follow-up sessions.

Results: Overall, 20 patients (12 with CPT1D, 4 with CPT2D, and 4 with CACTD) with disorders of mitochondrial carnitine–acylcarnitine cycle were diagnosed by NBS. The overall incidence of these disorders was one in 203,518 newborns. In total, 11 patients with CPT1D exhibited increased C0 levels and C0/(C16 + C18) ratios. In all patients of CPT2D, all long chain acyl-carnitines levels were elevated except for case 14 having normal C12 levels. In all patients with CACTD, all long chain acyl-carnitines levels were elevated except for case 17 having normal C12, C18, and C18:1 levels. Most patients with CPT1D were asymptomatic. Overall, two of 4 patients with CPT2D did not present any clinical symptom, but other two patients died. In 4 cases with CACTD, the disease was onset after birth.

Abbreviations: CPT1, carnitine palmitoyltransferase 1; CPT2, carnitine palmitoyltransferase 2; CACT, carnitine-acylcarnitine translocase; CPT1D, carnitine palmitoyltransferase 1 deficiency; CPT2D, carnitine palmitoyltransferase 2 deficiency; CACTD, carnitine-acylcarnitine translocase deficiency; NBS, newborn screening; C0, free carnitine; C2, Acetylcarnitine; C3, Propionylcarnitine; C4, Butyrylcarnitine; C12, Laurylecarnitine; C14, Myristoylcarnitine; C16, Palmitoylcarnitine; C16:1, Palmitoylecarnitine; C18, Octadecanoylcarnitine; C18:1, Oleoylcarnitine; MS/MS, tandem mass spectrometry; DBS, dried blood spot; NGS, next-generation sequencing; PCR, Polymerase chain reaction-restriction.
INTRODUCTION

Carnitine cycle is essential for transporting long-chain fatty acids into the mitochondrial matrix for β-oxidation (Watkins et al., 2007). Mitochondrial carnitine–acylcarnitine cycle is an important component of carnitine cycle, which consists of carnitine palmitoyl-transferases 1 (CPT1), carnitine palmitoyl-transferases 2 (CPT2), and the transporter protein carnitine-acylcarnitine translocase (CACT), which can uptake fatty acyl-CoAs across the mitochondrial membrane (Lodhi and Semenovich, 2014). First, CPT1 located on the outer mitochondrial membrane converts the long-chain acyl-CoAs to their acylcarnitine equivalents. Further, acyl-carnitines are transported into the mitochondrial matrix by CACT. In the end, acyl-carnitine is converted back to the acyl-CoA species and carnitine by CPT2 associated with the inner mitochondrial membrane (McGarry and Brown, 1997). CPT1 deficiency (CPT1D), CPT2 deficiency (CPT2D), and CACT deficiency (CACTD) are rare autosomal inherited recessive disorders, and the causative genes are CPT1A, CPT2, and SLC25A20, respectively (Wieser et al., 2003; Collins et al., 2010; Indiveri et al., 2011). Differences in the age of onset and clinical manifestations were observed in these disorders (Houten and Wanders, 2010). Late onset forms may present muscular symptoms such as myalgia, myoglobinuria, and muscle weakness during adolescence or adulthood. The condition can be triggered by fasting, illnesses, or high energy demand resulting in hypoketotic hypoglycaemia, hepatomegaly, cardiomyopathy, liver dysfunction, seizures, and sudden death at an early age. Disorders of mitochondrial carnitine–acylcarnitine cycle present different mortality and morbidity rates. In particular, CACTD was characterized with high mortality (Baruteau et al., 2014; Houten et al., 2016). Early detection and medical interventions can prevent individuals from metabolic decompensation and improve prognosis (Maguolo et al., 2020).

Infants with these diseases presented characteristic acylcarnitine profile are detectable by using tandem mass spectrometry (MS/MS), which has been widely implemented in NBS. With the application of MS/MS, the diagnosis of these disorders through newborn screening has become easier (Wilkken et al., 2003). The combined incidence of disorders of mitochondrial carnitine–acylcarnitine cycle was thought to be rare, which is estimated to be 1:186,833 in mainland China, 1:250,000 to 1:666,671 in Australia, Germany, and c.1:189,136 in the United States (Lindner et al., 2010; Deng et al., 2020). Disorders of mitochondrial carnitine–acylcarnitine cycle have great phenotypic variability and molecular heterogeneity. Herein, we present our over 12-years experience of NBS for the diagnosis and treatment of disorders of mitochondrial carnitine–acylcarnitine cycle in Zhejiang Province, China. The aim of this study was to determine the incidence and biochemical, clinical, and genetic characteristics of these disorders by NBS. With this study, the awareness about these rare disorders can be improved, and further implications of treatment can be considered.

MATERIALS AND METHODS

Study Population

From January 2009 to June 2021, 4,070,375 newborns were screened by MS/MS at Children’s Hospital, Zhejiang University School of Medicine. Among 4,070,375 participants who were recruited in this study, 3,784,837 were normal-term infants, 276,482 were premature infants, and 9,056 were post-term infants. The ratio of male to female was 1:1:1. The Ethical Committee of Children’s Hospital, Zhejiang University School of Medicine approved this research. The information sheet with consent information containing the explanation on the aim of this study was sent to participants and their parents and was signed by participants’ parents.

NBS for Disorders of Mitochondrial Carnitine–Acylcarnitine Cycle

Dried blood spot (DBS) samples were randomly collected between 3 and 7 days after birth and delivered through cold-chain transportation to the NBS centre of Children’s Hospital,
Zhejiang University School of Medicine within 3 days. Acylcarnitine profiles were assessed at our centre using NeoBase™ MS/MS reagent kits (PekinElmer, United States) according to the manufacturers’ protocol. Newborns with elevated C0 levels and/or C0/(C16 + C18) ratios were identified to have CPT1D. Newborns with decreased C0 levels and/or C0/(C16 + C18) ratios and/or elevated C12-C18:1 level were identified to have CPT2D or CACTD. Newborns were subjected to further confirmatory tests if the initial screening value exceeded the diagnostic cut-off. Newborns were subjected to a repeated test if the initial screening value was equal to or exceeding the screening cut-off. If the second screening results were still positive, confirmatory detection tests were performed, including biochemical laboratory tests and genetic analysis.

Genetic Testing
Genomic DNA was extracted from patients. Genetic testing was performed by Genetic Diagnostic Laboratory at Children’s Hospital, Zhejiang University School of Medicine (Hangzhou, Zhejiang, China). The target next-generation sequencing (NGS) was used on the probands with a target sequencing panel covering 306 known genes associated with inherited metabolic disorders. All potentially pathogenic mutations identified by NGS were further confirmed via Sanger sequencing. PolyPhen-2, PROVEAN, and Mutation Taster were used to predict the pathogenicity of the missense variants. The Structure stability analysis of novel missense variants were performed by Chimera software, and the three-level structure of protein was obtained. We selected the amino acid sequence and optimised the structure to find out whether the mutant amino acid triggers the atoms clash and contact. The three-dimensional structure of the protein was constructed after mutation, and the effect of mutation on protein stability was analysed.

Diagnosis and Follow-Up
Diagnosis was assessed by metabolic disease specialists based on the patients’ free carnitine and acylcarnitine levels, genetic variations, as well as additional clinical symptoms. All confirmed patients were followed up in our hospital. Dietary guidance including more frequent feeding, avoiding fasting, limiting fat intake, and appropriate supplementation of l-carnitine were applied for the confirmed patients. The follow-up time was once every 3–6 months if the confirmed patients presented stable performances. Patients were regarded as lost to follow-up if the follow-up time exceeded over 3 months and the patient still did not return to the clinical centre. The monitoring items included physical and biochemical examinations; levels of free carnitine and acylcarnitine, blood glucose, lactic acid, and blood ammonia; and blood routine test.

RESULTS

Incidences Determined From NBS
In this study, 4,070,375 newborns were screened and 20 patients (12 with CPT1D, 4 with CPT2D, and 4 with CACTD) were identified, with a total incidence of one in 203,518 live births. The incidence of CPT1D, CPT2D, and CACTD was 1:339,197, 1:1,017,593, and 1:1,017,593, respectively. Among all the disorders of mitochondrial carnitine–acylcarnitine cycle, CPT1D was the most prevalent. There were two pairs of monozygotic twins among patients with CPT1D.

Initial Screening Results of Acylcarnitine Levels
Overall, 11 patients (91.7%) with CPT1D had increased C0 levels and C0/(C16 + C18) ratios. C0 levels and C0/(C16 + C18) ratios of case 12 were normal in initial screening accompanied with lower C12-C18:1 level. In these patients, the average C0 level was 125.1 ± 61.68 μmol/L (range: 14.84–240.28 μmol/L) and C0/(C16 + C18) was 206.3 ± 278.5 (range: 25.59–1,007.27).

Overall, two of 4 patients with CPT2D had low C0 levels, and those of other two patients were normal. Long chain acyl-carnitines levels were elevated except in case 14 with normal C12 levels. The C14, C16, C16:1, C18, and C18:1 levels were 1.59 ± 0.25, 19.36 ± 2.33, 1.69 ± 0.18, 4.28 ± 0.74, and 6.67 ± 0.89 μmol/L, respectively. The ratios of long-chain acyl-carnitines to C0 were decreased and those to C2 and C3 were increased in all cases (C16 + C18:1)/C2, C14/C3, C16/C3, C16:1/C3, C18/C3, C18:1/C3, (C16 + C18:1)/C3, and C0/(C16 + C18) were 3.6 ± 2.7, 8.2 ± 2.55, 89.36 ± 53.08, 8.39 ± 5.25, 23.89 ± 14.61, 33.41 ± 21.43, 122.8 ± 73.72, and 0.51 ± 0.29, respectively.

In total, three patients with CACTD had decreased C0 levels. ALL C0/(C16+C18) ratios were decreased. All long-chain acyl-carnitines levels were elevated except in case 17 with normal C12, C18, and C18:1 levels. The C14, C16, and C16:1 levels were 1.33 ± 0.54, 18.97 ± 8.5, and 1.5 ± 0.7 μmol/L, respectively. All the ratios of long-chain acyl-carnitines to C2 and C3 were increased except in case 17 with normal C18/C3 level. The (C16 + C18:1)/C2, C14/C3, C16/C3, C16:1/C3, C18/C3, C18:1/C3, (C16 + C18:1)/C3, and C0/(C16 + C18) were 2.84 ± 1.71, 1.43 ± 0.45, 20.52 ± 7.99, 1.63 ± 0.51, 3.57 ± 1.72, 6.42 ± 4.09, 26.9 ± 11.33, and 0.38 ± 0.13, respectively.

C14/C3, C16/C3, C16:1/C3, C18/C3, C18:1/C3, and (C16 + C18:1)/C3 ratios were higher in patients with CPT2D when compared with those with CACTD. The differences were statistically significant (p = 0.038, 0.042, 0.042, 0.032, 0.048, and 0.042, respectively) (Table 1).

Initial Clinical Manifestations
The follow-up period of these patients lasted from 7 days to 4 years. Among 12 patients with CPT1D, 10 patients were asymptomatic. Case 2 presented clinical symptoms after birth, including hyperammonaemia and metabolic acidosis and passed away at 18 days-point. Follow-up data of case 1 were not available.

Patients 13 to 16 were identified as having CPT2D. Patient 13 died suddenly at 8 months at home with no available data. Patient 14 presented with poor feeding, poor response, and hypoglycaemia. Her condition deteriorated rapidly, and she died at 10 days after birth. No clinical symptoms were found in patients 15 and 16; however, patient 15 had incomplete right
bundle branch block in ECG, and patient 16 presented transient increase in alanine aminotransferase (ALT; 102 U/L) level.

Patients 17 to 20 were identified to have CACTD. All the patients had disease onset after birth. They presented feeding dysfunction, poor response, hypoglycaemia [1.9–3.2 mmol/L (normal range 3.6–6.1 mmol/L)], acidosis [1.8–17 mmol/L (normal range 0.5–1.6 mmol/L)], and hyperammonaemia [52–226 μmol/L (normal range 9–30 μmol/L)]. After diet management, l-carnitine supplementation, and acidosis correction, the clinical presentations and biochemical results of case 17 became normal, and the data were good after 15-months follow-up. Case 18 developed hepatic impairment, hepatomegaly, and cardiac hypertrophy; further, the parents stopped the treatment, and the infant died at the age of 2 months. The condition of cases 19 and 20 deteriorated rapidly, and they died at 7 days after birth (Table 2).

**Genetic Findings**

A total of 14 distinct mutations were identified in CPT1A gene; 85.72% (12/14) were missense, 7.14% (1/14) were deletion, and 7.14% (1/14) were splicing variants. Overall, 11 of these CPT1A variants were novel, and the other three were previously reported. The most frequent mutation was c.1910C > A (p.S637T), with an allelic frequency of 16.67% (4/24). The relatively frequent mutations were c.740C > T (p.P247L) and c.1328T > C (p.L443P), and each of mutation was identified three times, with an allelic frequency of 12.5% (3/24). c.2125G > A (p.G709R) and c.1295C > T (p.P432L) were each identified three times, and each of mutation was identified only once.

A total of six distinct mutations were identified in CPT2 gene. Among which, 83.33% (4/6) were missense, and 16.67% (2/6) were frameshift variants. Overall, three of these CPT2 variants were novel. The most frequent mutation was c.1711C > T (p.S637T), with an allelic frequency of 12.5% (3/24). c.205G > A (p.A749H), c.2125G > A (p.L443P), and each of mutation was identified only once.

For all these novel missense variants, all were predicted to be potentially pathogenic by Polyphen-2, PROVEAN, and the MutationTaster predictor (Table 3). Structure stability analysis was performed using Chimera version 1.15. Atoms clash and contacts decreased structure stability. c.740C > T (p.P247L), c.1328T > C (p.L443P), c.1817G > A (p.R606H), c.1910C > A (p.S637T), c.2246G > A (p.A749H), c.205G > A (p.V69M),

### Table 1 | Initial screening results of acylcarnitine levels in Mitochondrial Carnitine-Acylcarnitine Cycle Disorders.

| Acylcarnitine index | C0 | C2 | C3 | C12 | C14 | C16 | C16:1 | C18 | C18:1 | C0/(C16+C18) |
|---------------------|----|----|----|-----|-----|-----|-------|-----|-------|---------------|
| CPT1D               |    |    |    |     |     |     |       |     |       |               |
| 1                   | 119.08 | 11.01 | 0.89 | 0.03 | 0.03 | 0.29 | 0.02  | 0.16 | 0.16  | 237.33        |
| 2                   | 110.8 | 13.1 | 1.28 | 0.03 | 0.01 | 0.07 | 0.01  | 0.04 | 0.03  | 1,007.27      |
| 3                   | 156.37 | 38.33 | 2.01 | 0.05 | 0.08 | 0.86 | 0.06  | 0.27 | 0.3   | 138.01        |
| 4                   | 66.9 | 23.3 | 1.19 | 0.06 | 0.09 | 0.32 | 0.04  | 0.18 | 0.64  | 133.8         |
| 5                   | 117.45 | 35.71 | 1.86 | 0.08 | 0.11 | 0.37 | 0.05  | 0.17 | 0.55  | 217.5         |
| 6                   | 165.49 | 38.16 | 2.3 | 0.14 | 0.15 | 0.76 | 0.09  | 0.19 | 0.2   | 174.2         |
| 7                   | 240.28 | 33.83 | 3.21 | 0.08 | 0.08 | 0.59 | 0.05  | 0.17 | 0.25  | 316.16        |
| 8                   | 131.13 | 15.47 | 2.41 | 0.01 | 0.02 | 0.11 | 0.01  | 0.1   | 0.05  | 624.43        |
| 9                   | 199.04 | 28.7 | 2.42 | 0.06 | 0.09 | 0.79 | 0.05  | 0.23 | 0.25  | 195.14        |
| 10                  | 172.35 | 23.03 | 0.83 | 0.02 | 0.03 | 0.2  | 0.01  | 0.12 | 0.06  | 538.59        |
| 11                  | 72.46 | 31.68 | 3.66 | 0.05 | 0.09 | 0.37 | 0.04  | 0.15 | 0.56  | 139.35        |
| 12                  | 14.84 | 4.67 | 0.46 | 0.01 | 0.03 | 0.4  | 0.02  | 0.18 | 0.27  | 25.59         |

### Table 2 | CPT2D

| Acylcarnitine index | C0 | C2 | C3 | C12 | C14 | C16 | C16:1 | C18 | C18:1 | C0/(C16+C18) |
|---------------------|----|----|----|-----|-----|-----|-------|-----|-------|---------------|
| 13                  | 25.34 | 23.83 | 0.19 | 0.72 | 1.85 | 17.87 | 1.63 | 5.92 | 7.78 | 0.91 |
| 14                  | 5.86 | 11.47 | 1.68 | 0.23 | 1.24 | 22.31 | 1.54 | 4.24 | 5.9 | 0.22 |
| 15                  | 12.41 | 3.27 | 0.13 | 0.59 | 1.61 | 17.15 | 1.63 | 4.54 | 7.02 | 0.57 |
| 16                  | 9.25 | 7.33 | 0.17 | 0.47 | 1.69 | 20.09 | 1.96 | 4.58 | 5.98 | 0.37 |

### Table 3 | CACTD

| Acylcarnitine index | C0 | C2 | C3 | C12 | C14 | C16 | C16:1 | C18 | C18:1 | C0/(C16+C18) |
|---------------------|----|----|----|-----|-----|-----|-------|-----|-------|---------------|
| 17                  | 5.56 | 11.11 | 0.95 | 0.18 | 0.73 | 8.8 | 0.9 | 1.07 | 2.01 | 0.56 |
| 18                  | 7.24 | 7.96 | 0.63 | 0.89 | 1.08 | 15.23 | 1 | 3.07 | 7.43 | 0.4 |
| 19                  | 6.86 | 6 | 0.88 | 0.4 | 1.52 | 24.36 | 1.9 | 4.12 | 6.15 | 0.24 |
| 20                  | 10.29 | 12.83 | 1.31 | 0.65 | 1.99 | 27.49 | 2.39 | 4.73 | 6.27 | 0.32 |

**Cutoff value:** C0 10.28–54.24 μmol/L; C2 3–50 μmol/L; C3 0.43–3.8 μmol/L; C12 0.03–0.28 μmol/L; C14 0.01–0.23 μmol/L; C16 0.07–0.40 μmol/L; C18 0.49–6.00 μmol/L; C23 1.02–4.99 μmol/L; C12:1 0.38–2.92 μmol/L; C0/(C16 + C18) 2.76–35.1; C16 + C18 1/(C2) 0.11–0.54; C14/C3; C16/C3 0.35–4.92; C16/C3 0.01–0.34; C18/C3 0.6–1.69; C16 + C18 1/C3 0.71–7.21.
c.2125G > A (p.G709R), and (p.P432L). c.1054T > C (p.F352L) might cause 5, 5, 3, 1, 3, 7, 37, and one atom clash and contacts, respectively. No atom clash and contacts were caused by c.1295C > T (p.P432L), c.979C > T (p.H327T), and c.1131G > C (p.G377A). Atoms clash and contact are shown in yellow lines in Figure 1.

**DISCUSSION**

In this study, 20 patients with disorders of mitochondrial carnitine–acylcarnitine cycle were identified (12 with CPT1D, 4 with CPT2D, and 4 with CACTD) in approximately 4 million newborns in Zhejiang province, China between 2009 and 2021. The data revealed the largest series of cases with disorders of mitochondrial carnitine–acylcarnitine cycle detected by NBS in the Chinese Population. The incidence of newborns with disorders of mitochondrial carnitine–acylcarnitine cycle was 1:790,567 (CPT1D: 1:339,197; CPT2D: 1:1,017,593; and CACTD: 1:709.996) (Deng et al., 2013). Incidence of these disorders in Taiwan was 1:263,523 (CPT1D: 1:546,128, CPT2D: 1:1,014,237, and CACTD: 1:709.996) (Deng et al., 2020). Incidence of these disorders in the United States was 1:250,000 to 1:666,667 (Lindner et al., 2010). Disorders of mitochondrial carnitine–acylcarnitine cycle seem to be rare diseases in general population. The incidence of these disorders, especially that of CPT1D, in Zhejiang province seems to be higher than that reported in previous studies. This difference may be due to the awareness of these disorders, ethnic backgrounds, different cut-off values, recall criteria, and development of diagnostic methods. Previous reports revealed that these disorders may present normal acyl-carnitine levels at birth, resulting in false-negative cases (Dowsett et al., 2017). Case 12 with CPT1D was overlooked at the initial screening. Hence, the actual incidence may be higher than the reported data. A looser cut-off value can decrease false-negative cases but increase the actual incidence may be higher than the reported data. A previous report revealed that they have developed second-tier molecular tests for these diseases (Lin et al., 2020).

NBS plays an important role in the early detection of deficiency in enzymes of mitochondrial carnitine–acylcarnitine cycle.
### TABLE 3 | Variants detected in confirmed patients with CPT1D, CPT2D, CACTD.

| No | Nucleotide | Protein | Location | Effect | Frequency(%) | PolyPhen-2 | PROVEAN | Mutation Taster | Prediction of pathogenicity | References |
|----|------------|---------|----------|--------|--------------|------------|----------|----------------|--------------------------|------------|
| CPT1A |
| 1 | c.740C>T | p.P247L | Exon3 | Missense | 12.5 | D (1) | D (-8.135) | D (0.999) | Novel |
| 2 | c.1328T>C | p.L443P | Exon11 | Missense | 12.5 | D (1) | D (-5.826) | D (0.999) | Novel |
| 3 | c.1817G>A | p.R606H | Exon10 | Missense | 8.33 | D (1) | D (-4.557) | D (0.999) | Novel |
| 4 | c.979C>T | p.H327T | Exon10 | Missense | 4.16 | D (0.995) | D (-8.678) | D (0.999) | Novel |
| 5 | c.1336G>A | p.G446S | Exon11 | Missense | 4.16 | D (0.995) | D (-5.351) | D (0.999) | Novel |
| 6 | c.1910C>T | p.S637T | Exon16 | Missense | 16.67 | D (1) | N (-0.945) | P (0.998) | Novel |
| 7 | c.281+1G>A | — | Exon4 | Splicing | 8.33 | B (0.003) | D (-8.203) | D (1) | Novel |
| 8 | c.956G>A | p.G319V | Exon9 | Missense | 8.33 | B (0.003) | D (-8.203) | D (1) | Novel |
| 9 | c.804delG | p.F269Sfs*3 | Exon8 | Frameshift | 12.5 | N/A | N/A | N/A | Novel |
| 10 | c.205G | — | Exon6 | Deletion | 12.5 | N/A | N/A | N/A | Novel |
| 11 | c.2246G>A | p.R749H | Exon19 | Missense | 8.33 | D (1) | N (-0.771) | D (0.999) | Novel |
| 12 | c.1131G>G | p.E377D | Exon10 | Missense | 8.33 | D (1) | N (-0.771) | D (0.999) | Novel |
| 13 | c.577delC | p.M194* | Exon6 | Deletion | 8.33 | N/A | N/A | N/A | Novel |
| 14 | c.1295C>T | p.P432L | Exon11 | Missense | 16.67 | D (1) | D (-7.054) | D (0.999) | Novel |
| CPT2 |
| 15 | c.888dupT | p.J332Hfs*2 | Exon4 | Frameshift | 12.5 | N/A | N/A | N/A | Novel |
| 16 | c.1711C>A | p.S571T | Exon5 | Missense | 37.5 | D (0.985) | D (-6.169) | D (0.999) | Novel |
| 17 | c.520G>A | p.G174L | Exon4 | Missense | 37.5 | D (0.985) | D (-6.169) | D (0.999) | Novel |
| 18 | c.896insGGGCAGAGCTC | — | Exon4 | Frameshift | 12.5 | N/A | N/A | N/A | Novel |
| SLC25A20 |
| 19 | c.1054T>C | p.F352L | Exon4 | Missense | 12.5 | B (0.118) | D (-5.229) | D (0.999) | Novel |
| 20 | c.1301T>C | p.F434S | Exon4 | Missense | 12.5 | B (0.118) | D (-5.229) | D (0.999) | Novel |

Reference sequence for CPT1A, CPT2, SLC25A20 are NM_001876.3, NM_000098.2, NM_000098.3 respectively. The previously unreported novel variants of this study are in boldface type. N/A: not available. PolyPhen-2: http://genetics.bwh.harvard.edu/pph2/, HVAR score ranges from 0 (neutral, N) to 1 (damaging, D), B: benign, PROVEAN: http://provean.jcvi.org/ index.php, score ranges from ≤ -2.5 (detrimental, D) to > -2.5 (neutral, N). Mutation Taster: http://www.mutationtaster.org/, a score close to one indicates a high "security" of the prediction (P: polymorphism, D: disease causing). Novel mutations are in boldface type.

---

cycle (Wilcken et al., 2003). Most patients with CPT1D presented increased C0 levels and C0/(C16 + C18) ratios and/or decreased long-chain acyl-carnitines levels. For instance, patient 12 with normal C0 levels and C0/(C16 + C18) ratios was overlooked at the initial screening and exhibited slight reduction of C12 to C18:1 level. Milder forms of CPT1D may present normal growth and development following a strict diet management and follow-up (Gan et al., 2021). CPT1D can be triggered by fasting or illnesses associated with a low C18:1 level (particularly C16 and C18:1) and/or decreased C0, C2 levels were the major characteristics in CACTD and CPT2D. Some patients had normal concentrations of C12, C14, C16, C18, and C18:1. Elevation of (C16 + C18:1)/C2 ratios could reduce the false negative rate and improve the sensitivity (Sigauke et al., 2003; Edmondson et al., 2017; Tajima et al., 2017; Tang et al., 2019). However, this ratio sometimes may be normal (de Sain-van der Velden et al., 2013; Edmondson et al., 2017). The ratio of several long-chain acyl-carnitines to C3 like C14/C3, C16/C3, C18/C3, and (C16 + C18:1)/C3 can be used as better indices for CPT2D screening (Edmondson et al., 2017). In this study, it was observed that C14/C3, C16/C3, C16:1/C3, C18:1/C3, and (C16 + C18:1)/C3 ratios were increased in all patients with CACTD and CPT2D, which were significantly higher in CPT2D; this might be considered to distinguish between these two similar diseases. The results might be caused by very low concentrations of C3 levels in patients with CPT2D.

Patients with CPT1AD presented normal growth and development following a strict diet management and follow-up (Gan et al., 2021). CPT1D can be triggered by fasting or illnesses...
and presented with hypoketotic hypoglycaemic episodes and hepatomegaly in the early period of life; few cases may die in neonatal period (Baruteau et al., 2014; Fohner et al., 2017). Several cases with mild cardiomegaly, heartbeat disorders, or distal renal tubular acidosis have been reported (Olpin et al., 2001; Yu et al., 2021). Most patients with CPT1D had no clinic symptoms and only one case presented with hyperammonaemia and metabolic acidosis and died in the early neonatal period. Additionally, data suggested that early diagnosis and proper treatment resulted in good prognosis in patients with CPT1D. It remains to be observed whether patients with CPT1D will present further clinical symptoms. Overall, three different phenotypes of CPT2D have myopathic, lethal neonatal, and severe infantile forms. The most common form of CPT2D is the myopathic form, and the symptoms in 70% cases of this form were presented during 0–12 years of ages. The most common clinical symptoms were myalgia, myoglobinuria, and muscle weakness trigged by exercise and infection (Joshi et al., 2014; Joshi and Zierz, 2020). The severe infantile forms always presented hypoketotic hypoglycaemia, hepatomegaly, metabolic acidosis, cardiac manifestations, weakness, seizures, and sudden death (Sigauke et al., 2003). The lethal neonatal form is fatal, which causes death during the neonatal period (Isackson et al., 2008; Du et al., 2017). Overall, 4 CPT2D cases were detected in this study. One lethal neonatal form (patient 14) presented metabolic acidosis and hypoketotic hypoglycaemia and died soon in the neonatal period. One severe infantile form (patient 13) presented sudden death at 8 months at home without any available data. The two remaining cases (patients 15 and 16) were asymptomatic along with incomplete right and transient elevation of ALT, respectively. Critically ill patients with CACTD presented a severe phenotype in the neonatal time, including rapidly progressive condition and

![FIGURE 1](structure-stability-analysis.png)
a high fatality rate (Chen et al., 2020). Late onset form has been
less common (Morris et al., 1998). In this study, the 4 cases with
CACTD presented feeding dysfunction, poor response, hypoglycaemia, metabolic acidosis, hepatic impairment, hepatomegaly, and cardiac hypertrophy. In addition, two patients died in the early neonatal period, and 1 case died at 2 months after birth. Patient 17 survived. Although CACT
deficiency diagnosed via NBS had a surely high mortality rate,
early detection and treatment may save lives.

In general, more than 30 CPT1A pathogenic mutations have been
reported (Tsukubayama et al., 2010; Gan et al., 2021). c.1436C >
T (p.P479L) was the common mutation in northern Canada,
Greenland, Colombia, and the native Alaskan population (Park
et al., 2006). Moreover, c.2129G > A (p.G710E) was mainly
detected in the US Alaskan and Hutterite populations, and a
homozygous mutation might lead to severe clinical
manifestations (Prasad et al., 2001; Prip-Buus et al., 2001).
Hotspot mutations with CPT1D in the Chinese population
have not yet been reported, c.1910C > A (p.S637T), c.740C >
T (p.P247L), and c.1328T > C (p.L443P) presented highest
occurring mutations in this study and might be the potential
hotspot variants in Zhejiang province of South China.

Seventy pathogenic variants in CPT2 gene were reported and
phenotype–genotype association was observed in CPT2D (Joshi
et al., 2014). c.680C > T (p.P227L), c.1923_1935del, and c.983A >
G (p.D328G) were thought to be correlated with lethal neonatal
and severe infantile forms and generally not detected in patients
with myopathic forms (Isackson et al., 2006; Isackson et al., 2008).
Furthermore, the c.338C > T (p.S113L) mutation was detected in
almost 70% patients with myopathic forms (Joshi et al., 2014;
Fontaine et al., 2018). The c.338C > T (p.S113L) compound
heterozygotic patients were easily triggered by low temperature
compared with c.338C > T (p.S113L) homozygotic patients.
Patients with truncating mutations were significantly easily
triggered by fasting compared with those with missense
mutations on both two alleles. The c.338C > T (p.S113L)
mutation of CPT2 is a common variant in the Caucasian
population, whereas c.1148T > A (p.F383Y) mutation is common in Japanese population (Yasuno et al., 2008).
According to dataset, the most frequent mutation was c.1711C
> A (p.P571T), which was previously reported in the northern
China and might be the potential hotspot of CPT2D in Chinese
population (Qian et al., 2017).

More than 40 SLC25A20 pathogenic mutations have been
identified (Yan et al., 2017). Phenotype–genotype association in
CACTD have been reported previously. The c.241G > A (G81R)
mutation was associated with severe phenotype, whereas the
c.955insC mutation was associated with a milder form in the
Netherlands (Illst et al., 2001). c.199-10T > G mutation was the
most common in East Asia, which accounted for 83% of the
variant alleles in Chinese population (Tang et al., 2019; Chen
et al., 2020). The homozygous c.199-10T > G mutation was
associated with lethal neonatal form in Asian cases; two cases
with homozygous c.199-10T > G mutation in our study were died
early. c.199-10T > G mutation may cause premature protein
truncation and translocate enzyme without activity which may
explain the severe genotype of c.199-10T > G mutation (Hsu
et al., 2001). A compound heterozygous case with c.199-10T > G
and c.1A > G (p.M1V) mutation died at 6 days after birth (Yan
et al., 2017), whereas a case in our study with the same mutation
survived. Early timely treatment is crucial for CACTD and may
reverse the metabolic decompensation. This good prognosis of
our case might have benefited from early detection and early
management after NBS.

This study identified 11 novel CPT1A variants and 3 novel
CPT2 variants. Deletion (c.577delC (p.M194*)) and frameshift
variants (c.988dupT (p.I332Hfs*2) and c.895-896insGGCCAGAGGCTC (p.R303Gfs*6)) would result in truncated proteins which would potentially affect protein
function. All novel missense variants were predicted as
possibly pathogenic by bioinformatics analysis. We further
predicted structure stability analysis of novel missense
mutations. In addition to c.1295C > T (p.P432L), c.979C >
T (p.H327T), and c.1131G > C (p.G377A), all missense
variants might cause atom clash and contacts and decreased
structure stability of protein resulting in a loss-of-function
effect. Nevertheless, the pathogenicity of all these novel
variants needs to be confirmed by further functional
investigations.

**CONCLUSION**

In conclusion, disorders of mitochondrial
carnitine–acylcarnitine cycle, with a rare combined
incidence among newborns, were detected through NBS in
Zhejiang, China. Most of the patients presented different
typical acylcarnitine profiles. To be more specific, most
patients with CPT1D presented normal growth and
development, whereas those with CPT2D/CACTD had a high
mortality rate. Overall, 11 novel CPT1A variants and 3
novel CPT2 variants were identified, which further expanded
the mutational spectrum. All novel missense variants were
predicted as possibly pathogenic by bioinformatics analysis.
This study may help in enhancing overall awareness of
disorders of mitochondrial carnitine–acylcarnitine cycle
through clarifying the signification of early diagnosis and
proper treatment on the prevention and recovery of patients.

**DATA AVAILABILITY STATEMENT**

The data presented in the study are deposited in the Figshare.
The accession numbers were 10.6084/m9.figshare.18392345 and
10.6084/m9.figshare.18392426.

**AUTHOR CONTRIBUTIONS**

DZ performed the data analysis, drafted the initial manuscript,
reviewed and revised the manuscript; YC assisted with data
collection; XY revised the manuscript; ZH, JY, a followed the
patients and collected the clinical data; HM, YZ performed the
genetic tests, variants analysis; XH, BW designed and supervised
the study. All authors approved the final manuscript for submission and publication. These authors contributed equally to this work.

FUNDING
This work was supported by the National Key Research and Development Program of China (grant number: 2018YFC1002204), the National Natural Science Foundation of China (82073560); Basic Public Welfare Research Program of Zhejiang province (LGC19B050013).

ACKNOWLEDGMENTS
Thank you for all participation of patients and their family members.

REFERENCES
Baruteau, J., Sachs, P., Bouré, P., Brivet, M., Abdoul, H., Vianey-Saban, C., et al. (2014). Clinical and Biological Features at Diagnosis in Mitochondrial Fatty Acid Beta-Oxidation Defects: a French Pediatric Study from 187 Patients. Complementary Data. J. Inherit. Metab. Dis. 37 (1), 137–139. doi:10.1007/s10543-013-9628-9

Chen, M., Cai, Y., Xiong, H., Liu, M., Ma, F., et al. (2020). Late-Onset Carnitine-Acylcarnitine Translocase Deficiency with SLC25A20 c.199-10T>G Variation: Case Report and Pathologic Analysis of Liver Biopsy. Front. Pediatr. 8, 585646. doi:10.3389/fped.2020.585646

Chien, Y.-H., Lee, N.-C., Chao, M.-C., Chen, L.-C., Chen, L.-H., Chien, C.-C., et al. (2020). Incidence of Carnitine Palmitoyltransferase II Deficiency with a Mild Phenotype. J. Inherit. Metab. Dis. 101, 200–204. doi:10.1016/j.jimd.2020.07.013

d de Sain-van der Velden, M. G. M., Diekman, E. F., Jans, J. J., van der Ham, M., Heiner-Fokkema, M. R., Vaz, F. M., Maatman, R., Kluijtmans, L. A. J., van den Heuvel, E. L., et al. (2020). The Mitochondrial Carnitine/acylcarnitine Carrier: Function, Structure and Physiopathology. Annu. Rev. Physiol. 82, 110, 204. doi:10.1146/annurev-physiol-021115-105045

Houten, S. M., and Wanders, R. J. A. (2010). A General Introduction to the Biochemistry of Mitochondrial Fatty Acid β-oxidation. J. Inherit. Metab. Dis. 33 (5), 469–477. doi:10.1007/s10543-010-9061-2

Hsu, B. Y. L., Iacobazzi, V., Wang, Z., Harvie, H., Chalmers, R. A., Saudubray, J.-M., et al. (2001). Aberrant mRNA Splicing Associated with Coding Region Mutations in Children with Carnitine-Acylcarnitine Translocase Deficiency. Mol. Genet. Metab. 74, 248–255. doi:10.1006/mgme.2001.3235

Illi, L., van Rooyen, M. C. W. T., Jacobazzi, V., Oostheim, W., Ruitter, J. P. N., Williams, J. C., et al. (2001). Functional Analysis of Mutant Human Carnitine Acylcarnitine Translocases in Yeast. Biochem. Biophysical Res. Commun. 280 (3), 700–706. doi:10.1016/j.bbrc.2000.11.178

Indiveri, C., Iacobazzi, V., Tonazzi, A., Giangregorio, N., Infantino, V., Convertini, P., et al. (2011). The Mitochondrial Carnitine/acylcarnitine Carrier: Function, Structure and Physiopathology. Mol. aspects Med. 32, 223–233. doi:10.1016/j.mam.2011.10.008

Isackson, P. J., Bennett, M. J., Lichter-Konecki, U., Willis, M., Nyhan, W. L., Sutton, V. R., et al. (2008). CPT2 Gene Mutations Resulting in Lethal Neonatal or Severe Infantile Carnitine Palmitoyltransferase II Deficiency. Mol. Genet. Metab. 94 (4), 422–427. doi:10.1016/j.ymgme.2008.05.002

Isackson, P. J., Bennett, M. J., and Vladutiu, G. D. (2006). Identification of 16 New Disease-Causing Mutations in the CPT2 Gene Resulting in Carnitine Palmitoyltransferase II Deficiency. Mol. Genet. Metab. 89 (4), 323–331. doi:10.1016/j.ymgme.2006.08.004

Joshí, P. R., Deschauer, M., and Ziera, S. (2014). Carnitine Palmitoyltransferase II (CPTII) Deficiency: Genotype-Phenotype Analysis of 30 Patients. J. Neurol. Sci. 338, 107–111. doi:10.1016/j.jns.2013.12.026

Joshí, P. R., and Ziera, S. (2020). Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach. Molecules 25 (8), 1784. doi:10.3390/molecules25081784

Lin, Y., Liu, Y., Zhu, L., Le, K., Shen, Y., Yang, C., et al. (2020). Combining Newborn Screening: A Single Centre Experience. J. Inherit. Metab. Dis. 43 (3), 467–477. doi:10.1002/jimd.12206

Lindner, M., Hoffmann, G. F., and Matern, D. (2010). Newborn Screening for Disorders of Fatty Acid Oxidation: Experience and Recommendations from an Expert Meeting. J. Inherit. Metab. Dis. 33 (5), 521–526. doi:10.1007/s10543-010-9076-8

Lodhi, I. J., and Semenovich, C. F. (2014). Peroxisomes: a Nucleus for Lipid Metabolism and Cellular Signaling. Cell Metab. 19 (3), 380–392. doi:10.1016/j.cmet.2014.01.002

Maguolo, A., Rodella, G., Dinain, A., Nurti, R., Monge, I., Rigotti, E., et al. (2020). Diagnosis, Genetic Characterization and Clinical Follow up of Mitochondrial Fatty Acid Oxidation Disorders in the new era of Expanded Newborn Screening: A Single centre Experience. Mol. Genet. Metab. Rep. 24, 100632. doi:10.1016/j.ymgmr.2020.100632

McGarry, J. D., and Brown, N. F. (1997). The Mitochondrial Carnitine Palmitoyltransferase System - from Concept to Molecular Analysis. Eur. J. Biochem. 244 (1), 1–14. doi:10.1111/j.1432-1033.1997.0001.x

Morris, A. A. M., Olpin, S. E., Brivet, M., Turnbull, D. M., Jones, R. A. K., and Leonard, J. V. (1998). A Patient with Carnitine-Acylcarnitine Translocase Deficiency with a Mild Phenotype. J. Pediatr. 132, 514–516. doi:10.1016/s0022-3476(98)70030-7
Zhou et al.  

Mitochondrial Carnitine-Acylcarnitine Cycle Disorders

Olpin, S. E., Allen, J., Bonham, J. R., Clark, S., Clayton, P. T., Calvin, J., et al. (2001). Features of Carnitine Palmitoyltransferase Type I Deficiency. J. Inherit. Metab. Dis. 24 (1), 35–42. doi:10.1038/sj.jm.2500953

Park, J. Y., Narayan, S. B., and Bennett, M. J. (2006). Molecular Assay for Detection of the Common Carnitine Palmitoyltransferase 1A 1436(C>T) Mutation. Clin. Chem. Lab. Med. 44 (9), 1090–1091. doi:10.1515/CCLM.2006.196

Prasad, C., Johnson, J. P., Bonnefont, J. P., Dilling, L. A., Innes, A. M., Haworth, J. C., et al. (2003). Carnitine-acylcarnitine Transitocase Deficiency in North American Hutterites (Canadian and American): Evidence for a Founder Effect and Results of a Pilot Study on a DNA-Based Newborn Screening Program. Mol. Genet. Metab. 73 (1), 55–63. doi:10.1006/mgme.2001.3149

Prip-Buus, C., Thuillier, L., Abadi, N., Prasad, C., Dilling, L., Klasing, J., et al. (2017). Clinical and Molecular Characteristics of Carnitine Palmitoyltransferase 1A Mutation in the Hutterite Community. Mol. Genet. Metab. 73 (1), 46–54. doi:10.1006/mgme.2001.3176

Qian, J., Wang, X., Liu, J., Zhong, J., Le, Y., Melchior Tellier, L. C. A., et al. (2017). Applying Targeted Next Generation Sequencing to Dried Blood Spot Specimens from Suspicious Cases Identified by Tandem Mass Spectrometry-Based Newborn Screening. J. Pediatr. Endocrinol. Metab. 30 (9), 979–988. doi:10.1515/jpem-2017-0003

Sigaude, E., Rakheja, D., Kitson, K., and Bennett, M. J. (2003). Carnitine Palmitoyltransferase II Deficiency: A Clinical, Biochemical, and Molecular Review. Lab. Invest. 83 (11), 1543–1554. doi:10.1097/01.lab.0000096285.51765.83

Tajima, G., Hara, K., Tsumura, M., Kagawa, R., Okada, S., Sakura, N., et al. (2017). Newborn Screening for Carnitine Palmitoyltransferase II Deficiency Using (C16 + C18:1)/C2: Evaluation of Additional Indices for Adequate Sensitivity and Lower False-Positivity. Mol. Genet. Metab. 122 (3), 67–75. doi:10.1016/j.ymgme.2017.07.011

Tang, C., Liu, S., Wu, M., Lin, S., Lin, Y., Su, L., et al. (2019). Clinical and Molecular Characteristics of Carnitine-Acylcarnitine Translocase Deficiency: Experience with Six Patients in Guangdong China. Clinica Chim. Acta 495, 476–480. doi:10.1016/j.cca.2019.05.018

Tsujimura, T., Bonnefont, J. P., Dilling, L., Innes, A. M., Haworth, J. C., et al. (2003). Mutations of Carnitine Palmitoyltransferase II (CPT II) in Japanese Patients with CPT II Deficiency. Int. J. Genet. Mol. Personalized Med. 73 (5), 496–501. doi:10.1111/j.1399-0004.2008.00986.x

Yu, Y., Shen, L. H., Qiu, W. J., Zhang, H. W., Ye, J., Liang, L. L., et al. (2021). Screening Newborns for Inborn Errors of Metabolism by Tandem Mass Spectrometry. J. Pediatr. Endocrinol. Metab. 34 (23), 2304–2312. doi:10.1515/jpem-2020-0034

Conflict of Interest: Author YZ is employed by Zhejiang Bosheng Biotechnology Co, Ltd, Hangzhou, China.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhou, Cheng, Yin, Miao, Hu, Yang, Zhang, Wu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.